DSIP (Delta Sleep-Inducing Peptide): Complete Research Guide — Nonapeptide Sleep Architecture, Neuroendocrine Modulation & Human Data (2026)

What Is DSIP and What Makes Its Pharmacology Unique?

DSIP (CAS: 62568-57-4; sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; MW: 849.86 Da) is a nonapeptide with a unique amino acid sequence that does not belong to any known peptide family. Updated April 2026. It was isolated in 1977 by Georg Schoenenberger and colleagues at the University of Basel from the cerebral venous blood of rabbits subjected to low-frequency (“hypnogenic”) electrical stimulation of the intralaminar thalamic nuclei — a technique that reproducibly induces slow-wave sleep (SWS) in animals. The fraction of the collected venous blood that induced delta-wave EEG activity when infused IV into other animals was the fraction containing DSIP. The peptide was characterized and synthesized in 1977, and synthetic DSIP replicated the delta-wave EEG effects of the natural fraction (Schoenenberger et al., Eur Neurol, 1984 — PMID: 6548966).

What makes DSIP scientifically unusual is the persistence of its pharmacological “mystery” despite decades of research. Most bioactive peptides are characterized by the identification of their encoding gene, precursor protein, and specific receptor. For DSIP, none of these three has been found. No DSIP gene has been identified in the rabbit or any other species. No precursor peptide is known. No specific DSIP receptor has been characterized. DSIP-like immunoreactivity has been detected in brain and peripheral organs by radioimmunoassay (RIA) and immunohistochemistry, but this immunoreactivity may reflect peptides with structural similarity rather than DSIP itself. Kovalzon & Strekalova (2006) summarized this state in Journal of Neurochemistry: the evidence for DSIP as an endogenous sleep-promoting factor remains “extremely poorly documented and still weak” despite its documented biological activity in multiple species (PMID: 16539679).

Key Characteristics

What Are DSIP’s Documented Mechanisms?

Despite the absence of a characterized receptor, published research has documented multiple reproducible biological effects of DSIP across species. These effects have been studied via direct IV/SC administration, via DSIP antiserum injection (which reverses endogenous DSIP-like activity), and via structural analog studies. The biological effects are empirically documented even without a defined molecular mechanism.

Sleep Architecture Modulation: Delta Wave Enhancement

DSIP’s naming effect — enhancement of EEG delta wave activity during slow-wave sleep — has been reproduced in rabbits, rats, mice, and humans. IV administration produces increased time in delta (Stage 3–4) sleep and decreased wakefulness in published EEG studies. The effect follows a U-shaped dose-response: intermediate doses produce the maximum sleep-promoting effect; very low and very high doses produce attenuated effects. This U-shaped activity curve was documented by Graf & Kastin (1984) in their comprehensive review of DSIP biology and must be accounted for in research protocol design (Graf & Kastin, Neurosci Biobehav Rev, 1984 — PMID: 6145137).

HPA Axis Modulation: ACTH and Cortisol Reduction

DSIP reduces basal corticotropin (ACTH) levels and blocks ACTH release evoked by corticotropin-releasing hormone (CRH) injection in published studies. This stress-limiting action has been documented by Graf et al. (1984), Schoenenberger (1984), and multiple subsequent groups in rodent models. The reduction of ACTH/cortisol response under stress conditions — without affecting basal GH or other pituitary hormones at non-ACTH-relevant doses — is the basis for DSIP’s designation as a “stress-limiting factor” in the neuroendocrinological literature. DSIP has also been proposed to interact with components of the MAPK cascade and to show structural homology to glucocorticoid-induced leucine zipper (GILZ), potentially explaining some of its cortisol-related effects.

Somatotropic Axis: GH Release and Somatostatin Inhibition

Published studies document that DSIP inhibits somatostatin (SRIF) release from the hypothalamic median eminence in a dose-dependent manner via a dopaminergic mechanism, and simultaneously stimulates somatoliberin (GHRH) and GH release. This combination — removing the inhibitory brake (SRIF) while activating the stimulatory signal (GHRH) — produces net GH release. This GH-axis interaction is consistent with DSIP’s observed effect on slow-wave sleep, since GH is preferentially released during SWS and SRIF inhibition normally accompanies the GH pulse during deep sleep.

What Systems Has DSIP Been Investigated For?

Sleep Architecture Research

DSIP’s primary research application is in slow-wave sleep (SWS / delta sleep) biology. Published EEG studies in rabbits, rodents, and humans document enhancement of delta-wave power and increased SWS duration following IV DSIP administration. Schneider-Helmert & Schoenenberger (1981, 1983) published the foundational human sleep normalization data, documenting improved sleep quality in subjects with disturbed sleep patterns. The U-shaped dose-response and short plasma half-life are the key protocol design parameters for sleep research applications.

Stress and HPA Axis Research

DSIP has been investigated as a stress-limiting peptide in published animal models, counteracting experimentally induced stress situations, reducing cortisol response to stressors, and modulating circadian rhythms of locomotion. The interaction with the MAPK cascade and possible GILZ homology are proposed molecular mechanisms that remain under investigation.

Withdrawal Syndrome Research

Dick et al. (1984, European Neurology) published human data on DSIP in the treatment of withdrawal syndromes from alcohol and opioid dependence. The proposed mechanism involves DSIP’s interaction with the opioidergic system: published data documents DSIP acts antagonistically at opiate receptors and inhibits development of opioid and alcohol dependence in animal models. Human clinical studies published in the 1984 European Neurology symposium volume reported encouraging results in withdrawal management with IV DSIP. These are among the earliest published human interventional data for any research peptide in the sleep/neuroendocrine category.

Circadian Rhythm and Neuroendocrine Research

DSIP normalizes disrupted circadian rhythms of corticosteroid secretion and locomotion in published animal studies, and influences the circadian profiles of intracerebral neurotransmitter concentrations. MAO-A (monoamine oxidase A) induction in the brain has been documented following DSIP administration, suggesting broader monoaminergic neuromodulatory effects beyond direct sleep-state changes.

What Does the Human Research Data Show?

How Does DSIP Compare to Other Sleep and Neuroendocrine Research Peptides?

DSIP is the only compound in the YPB catalog with published delta-wave EEG data and direct slow-wave sleep architecture research. Selank and Semax (see the Selank Research Guide and Semax Research Guide) address cognitive and anxiolytic research without delta-wave sleep mechanism overlap. The Epitalon Research Guide covers the circadian and longevity research application that partially overlaps with DSIP’s circadian rhythm modulation research but operates through a different proposed mechanism.

What Should Researchers Know About DSIP Stability and Handling?

DSIP at 849.86 Da is a mid-small nonapeptide. Its short plasma half-life (~15 minutes) is a key protocol consideration, and DSIP structural analogs with improved metabolic stability have been developed specifically to address this limitation in research contexts.

Storage and Reconstitution

Lyophilized DSIP is stable at −20°C for up to 24 months. Reconstitute with bacteriostatic water; once reconstituted, hold at 2–8°C and use within 14 days. Avoid repeated freeze-thaw cycles. DSIP’s short half-life in biological systems means protocols requiring sustained exposure should account for rapid clearance when designing dosing intervals.

COA Verification

HPLC purity (≥98%) and MS confirmation at 849.86 Da is the standard quality protocol. The unique WAGGDASGE sequence has no known homolog in common peptide families, so sequence confirmation is straightforward by MS fragmentation. All YPB DSIP batches include lot-traceable COA documentation through the COA Library.

Key Research Findings: DSIP in 2026

Market Demand and Research Interest

How Can Researchers Offer DSIP Under Their Own Brand?

DSIP Wholesale Pricing & Margin Analysis

Contact the YPB team for confirmed Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. White-label brands offering DSIP alongside Selank and Semax create a comprehensive neurological research catalog covering the three primary Russian/European neuropeptide research lines: sleep architecture (DSIP), anxiolytic-cognitive (Selank), and cognitive-neuroprotective (Semax) — three distinct research tools from a single neuroendocrine research buyer audience. Download the full catalog for all neuroendocrine SKU pricing.

Methodology & Data Sources

References

Frequently Asked Questions

Key Takeaways

Research Takeaways

• Original 1977 isolation and delta-wave EEG naming effect: Schoenenberger-Monnier group Basel; synthetic DSIP reproduces delta-wave EEG and SWS promotion across rabbits, rodents, and humans (Schoenenberger 1984, PMID: 6548966).
• No gene, receptor, or precursor identified after 45+ years — “unresolved riddle” (Kovalzon & Strekalova 2006, PMID: 16539679); researchers must document this mechanistic uncertainty in protocols.
• U-shaped dose-response: Both too little and too much DSIP attenuates delta-wave effects; intermediate doses produce maximum activity (Graf & Kastin 1984, PMID: 6145137) — critical protocol design parameter.
• HPA axis stress-limiting: Reduces ACTH and blocks CRH-evoked ACTH release; proposed stress-limiting mechanism confirmed across multiple rodent laboratories.
• SRIF inhibition + GH stimulation: Dopaminergic SRIF inhibition from hypothalamic median eminence + GHRH stimulation → net GH release; physiologically coupling delta-sleep and GH secretion research.
• Published human data (small-N, early phase): 1981–1984 sleep normalization, withdrawal syndrome, and pain management studies; no large-scale RCT as of April 2026.
• Short plasma half-life (~15 minutes) — structural analogs with improved stability have been developed for research contexts requiring longer duration of action.

Business Takeaways

• $80 MSRP on both SKUs (5mg and 15mg) — contact YPB for confirmed wholesale pricing at Premier tier.
• ~4,000 monthly searches at low KD — dedicated sleep biology, neuroendocrine, and stress research audience distinct from GH-axis and healing categories.
• Only sleep-architecture-specific peptide in YPB catalog — EEG delta-wave data is unique to DSIP; no content overlap with any other guide.
• DSIP + Selank + Semax neuroendocrine trio covers sleep, anxiety-cognition, and neuroprotection from one Russian/European neuropeptide buyer audience.

Ready to add DSIP to your research catalog? Book a consultation with the YPB team.

[ypb_studies peptide=”dsip”]